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A physiologicalflow model is presented to account for plasma level double peaks based on cyclical 
gastric emptying and intestinal motility in the fasted state. Central to the model is the assumption 
that gastric emptying and intestinal transit rates will vary directly with the strength of  the contractile 
activity characteristic of  the fasted state motility cycle. Simulated curves clearly indicate that 
variable gastric emptying rates can result in variable absorption rates from the gastrointestinal 
tract and double peaks in the plasma level curves of  cimetidine. Vital to the occurrence o f  double 
peaks are (i) dosing time relative to phasic activity, (ii) variability in flow out o f  the stomach, 
and (iii) a small emptying rate constant Qs/Vs, for a period of  time within the first hour after 
administration. Variability in intestinal flow rates alone does not cause a double peak in the 
plasma level curve. Results of  the simulations, as well as experimental results, can be categorized 
according to the shapes of  the plasma level curves into four types: type A, Cp,,,~x(1) < Cpmax(2); 
type B, single peak; type C, Cpmax(1) > Cp,~x(2); type D, Cp,~ax(1) = Cpmax(2). Assuming that 
the experimental results were obtained from fasted subjects, with the time of  dose administration 
being a random variable, the frequency of  the experimental curves having shape A, B, C, or D 
correlates extremely well with theoretical predictions. It is concluded that variable gastric emptying 
rates due to the motility cycle can account for plasma level double peaks. Furthermore, variable 
gastric emptying rates combined with the short plasma elimination half-life and poor gastric 
absorption o f  cimetidine can be the cause o f  the frequently observed plasma level double peaks. 
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I N T R O D U C T I O N  
The rate and extent of  drug absorption after oral administration can 
be affected by the residence time of  the drug in the stomach and along the 
intestine. In turn, the residence time is dictated to a large extent by gastric 
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emptying and gastrointestinal motility. Because very little absorption of 
most drugs occurs from the stomach relative to the small intestine (1-3), 
drug is retained in the stomach until it is delivered to the small intestine 
and subsequently absorbed. For drugs with a high water solubility, dissolu- 
tion is fast and is most likely not a rate-limiting factor to drug absorption. 
Under these circumstances, gastric emptying may be a critical determining 
factor in drug absorption. 
Clements et al. (4) investigated the kinetics of acetaminophen with 
simultaneous radioisotopic measurement of gastric emptying. Results of 
their experiments strongly suggest gastric emptying was the rate-limiting 
step in the absorption of acetaminophen. Evidence of the importance of 
gastric emptying to drug absorption has also been provided indirectly by 
studying the absorption of one drug after pretreatment with a different drug 
that alters the rate of gastric emptying (5). 
Variability in stomach emptying rates and intestinal flow rates over the 
course of the entire absorption process after a single dose would likely 
result in variable absorption rates. In this case, absorption may not be 
simply first-order. This could result in a somewh~it complex plasma con- 
centration-time profile. For example, double peaks in the plasma concentra- 
tion-time profile were observed for acetaminophen when monoexponential 
emptying was interrupted by an interval of no emptying (4). Double peaks 
in the plasma level curve frequently occur after administration of cimetidine, 
an H2-receptor antagonist, as a liquid or tablet in the fasted state (6-9). 
Double peaks do not occur if cimetidine is administered intravenously or 
concomitantly with food. Other drugs known to exhibit double peaks are 
penicillamine, sobrerol, furosemide, prednisolone, propranolol, and aspirin 
(10-13, unpublished data). 
The phenomenon of double peaks has often been attributed to 
enterohepatic recycling (14,15). However, evidence for biliary excretion of 
cimetidine is weak since less than 1% of an 800-mg oral dose of cimetidine 
was recovered in the bile (16). More recently, Wagner (10) has postulated 
two different absorption sites in the gastrointestinal tract for penicillamine, 
but the physiological basis for two absorption sites is unclear. A more 
physiological basis for the observed double peaks is needed. This report 
presents a physiological model for the gastrointestinal absorption of 
cimetidine and demonstrates that it can account for the observed double 
peak phenomenon. A subsequent publication will generalize these con- 
clusions to drug and physiological variables that can give rise to this 
phenomenon. 
Fasted Gastrointestinal Motility 
Over the last 20 years, renewed interest in gastrointestinal (GI) motility 
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has led to the recognition of its cyclical nature in the fasted state. The cycle 
is characterized by four phases. Phase I is a quiescent period. Phase II 
consists of intermittent and irregular contractions. These contractions 
gradually increase in strength culminating in a short period of intense 
contractions called Phase III, the activity phase or the housekeeper wave. 
Phase IV is a brief transition period from Phase IlI to Phase I: however, 
Phase IV has been found only occasionally, if at all, by some authors (17-19). 
The active phase originates in the distal part of the stomach and 
duodenum and propagates distally through the small intestine, although 
not all contractions move the entire length of  the small intestine (20). 
Therefore, the motor activity has been called the migrating motor complex 
(MMC). Phase III is, therefore, usually present over a definite length of 
the bowel at any given time. Animal and human experiments have shown 
the complex originates simultaneously in the stomach and duodenum 
(21,22). 
In a recent review, Sarna et al. (23) reported that Phase III starts in 
the stomach prior to in the duodenum but ends in the stomach and 
duodenum at about the same time. Approximately 20% of the time, Phase 
III activity starts at a more distal site such as the jejunum and migrates 
caudad (24,25). 
The mean duration of  the MMC cycle in humans is in the range of 
80-150rain; mean values of 149, 90, and l l 0 m i n  have been observed 
(22,26,27). The cycle duration is highly variable ranging from 15 rain to 
greater than 3 hr (26). Phases I and II last 20-90 and 10-135 rain, respectively 
(21,22). The duration of Phase III in the stomach ranges from 3 to 25 rain 
(23,26,28). Phase III lasts for approximately 3 rain in the human duodenum 
(22,26). 
Contractions of varying intensity characteristic of the motility cycle 
would likely result in variable flow out of  the stomach and throughout the 
small intestine. This is the case in the jejunum and ileum where the 
volumetric flow rates were 1.28 and 0.5 ml/min during Phase III, respec- 
tively, but were only 0.58 and 0.17 ml/min during Phases I and II, respec- 
tively (29). However, very little is known about the volumetric flow rates 
out of the stomach and duodenum as they relate to the motility cycle. 
Gastric emptying of nonnutrient liquids has been reported as an 
apparent first-order process (22,26). Hunt and MacDonald (30) found mean 
emptying half-lives of 9, 21, and 37 min for pectin meals of 330, 750, and 
1250 ml, respectively. Bateman and Whittingham (31) found a mean half-life 
for gastric emptying of a 500 ml drink of approximately 22 rain with a range 
of 9-40 min. Some studies have suggested liquid emptying is not simply 
first-order but is variable (4). Recent studies in dogs have shown that gastric 
emptying of small volumes (25-150 ml) is related to the motility pattern, 
but emptying of larger volumes follows first-order kinetics (32). 
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Since GI  motility, gastric emptying, and intestinal transit rates are 
variable and since most drugs are studied in the fasted state, it seems 
reasonable to suggest that plasma level curves may exhibit double peaks 
due to this variability. Therefore, a physiological flow model has been 
developed to account for cyclical gastric emptying and intestinal motility 
in the fasted state and used to estimate the influence of this variation on 
the plasma level time curve of cimetidine. 
T H E O R E T I C A L  
The GI  tract is described as four serial compartments:  the stomach, 
duodenum, jejunum, and ileum. The plasma kinetics are described by a 
two-compartment  pharmacokinet ic  model representing the plasma from 
which drug is reversibly distributed and eliminated and the tissue. Figure 
1 is a schematic diagram of the model. A set of  six first-order linear 
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d A s / d t  = - ( O s / V s + K a s )  As 
d A d / d t  = - ( Q d / V d + K a d ) A d  + Q s / V s A s  
d A j / d t  = - ( Q j / V j + K a j ) A j  + Q d / V d A d  
d A i / d t  = - (Q i /V i  + Kai)Ai  + Qj/Vj  Aj 
d A p / d t  = KasAs + KadAd + Ka jA j  + Ka iA i  + K21A t  
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d A t / d t  = K 12 Ap - K21 At  
Fig. 1. Schematic diagram and set of differential equations describing the model. 
See Notation section for the meaning of the symbols. 
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differential equations mathematically describes the system (Fig. t). Initially, 
the dose (300 rag) is delivered to the stomach. The initial amount  is zero 
in all other compartments.  Drug is lost from the GI  compartments  by flow 
to the nearest distal compartment  or absorption into the plasma. Drug is 
gained in each intestinal compartment  by flow from the nearest proximal 
compartment.  
The following model assumptions are made: 
1. The volumetric flow rate is directly related to the strength of the 
contractile activity. As a result, the flow rate increases as the cycle proceeds 
from Phase I to Phase I I I  in each compartment.  
2. Flow rates exiting each compartment  are constant during a given 
phase of the motility cycle, however, vary from one phase to another. 
3. Compartmental  volumes are held constant. 
4. The only exception to 2 and 3 above is the initial stomach exiting 
flow rate and volume. For the first 20 min after drug administration, stomach 
emptying is governed by an exponential decrease in stomach volume accord- 
ing to Eq. 1. 
V~ = V~ -kt (1) 
Flow rate out of  the stomach, defined as the derivative of  volume with 
respect to time, is as follows: 
Q d  t) = - d V s /  dt = k V  ~ e -k '=  kV, (2) 
Therefore 
Q ~ ( t ) / V s ( t )  = k = a constant (3) 
A value of 0.025-0.033 for k is based on studies of  liquid emptying of a 
300-500 ml test meal (28,30,31). Therefore, even though stomach volume 
and exiting flow rate are allowed to vary with time initially, the differential 
equation describing drug concentration in the stomach is still first-order. 
5. The phasic activity and associated flow rates are propagated down 
the GI  tract in agreement with available data on the migratory nature of 
the motility complex. Phase I I I  is, therefore, always present somewhere in 
the GI  tract. 
6. Dissolution of the drug is not presently considered in the model. 
The drug is administered in solution as a bolus, and no precipitation of the 
drug occurs. Due to the high water solubility of cimetidine, dissolution is 
not expected to limit the rate of  drug absorption. 
7. The concentration of drug in each compartment  is homogeneous 
throughout. 
8. Gastric emptying is not altered in the model as a result of  the 
pharmacological action of cimefidine (33). 
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9. Other factors such as stomach or duodenal pH or osmolarity affect 
compartmental emptying rates minimally compared to gastrointestinal 
motility. 
The time of dose administration is considered to be a random variable 
of uniform distribution of length equal to the mean length of the motility 
cycle (105 min). Plasma levels of the drug result from stomach emptying 
and subsequent absorption, distribution, and elimination. These processes 
are governed by parameters related to GI physiology and the properties of 
cimetidine. The physiological model parameters are chosen to represent the 
GI motility cycle in the fasted state. 
Physiological  Parameters 
The motility cycle in the model is divided into three consecutive phases 
(I, II, and III) representing the physiological equivalents in the fasted state. 
A fourth phase corresponding to Phase IV motor activity, being relatively 
ill-defined and short, is not included in the model. The lengths of Phases 
I, II, and III used in the model can be found in Fig. 2. Model flow rates 
used as a function of phasic activity are illustrated in Fig. 2. The volumes 
of each compartment used in the model are listed in Table I. These param- 
eters are in the range of values reported in the literature (28,29,34,35). 
The migratory nature of the MMC was incorporated into the model 
by examining available literature data on the propagation velocity of Phase 
III. The mean length of  the gut activated simultaneously, the duration of 
Phase III and the lengths of each intestinal compartment (21,22,26). Figure 
2 also illustrates the phasic activity staggered down the GI tract as treated 
in the model. 
Parameters Related to Cimetidine 
The parameters for the iv kinetics, Klo, K12, K2~ and Vp were obtained 
by fitting the intravenous data obtained by Walkenstein et al. (9) to a 
two-compartment model with elimination from the central compartment. 
The respective values of 0.0132, 0.0175, 0.0224 rain -1, and 46147 ml were 
used in the model. 
Experimental rat jejunal perfusions at 1 mg/ml cimetidine concentra- 
tion provided intestinal permeabiiities as a function of pH from which 
absorption rate constants were calculated (unpublished data). Means and 
ranges of absorption rate constants for cimetidine in each GI compartment 
can be found in Table I. Values for Ka agree well with the reported mean 
pharmacokinetic value of 0.0478 rain -1 (14). 
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Fig. 2. Model flow rates as a function of gastrointestinal motility phase, 
depiction of the migrating myoelectric complex staggered down the GI 
tract, and illustration of defined regions A, B, C, and D (*-Phase I: 
**-Phase II: ***-Phase III). 
Table I. Cimetidine Absorption Rate Constants From and Volumes of 
Gastrointestinal Compartments 
Model Literature 
Physiological volume value (ml) Assumed 
space (ml) (reference) pH 
Experimental K~ (min -~) 
Mean Range 
Model K a 
(min -1 ) 
Stomach 100 n 50-1500 1-3 0.00064 . 0.0~304- 
(27,34) 0.00094 
Duodenum 30 25-75 5.5 0.084 0.064-0.11 
(33,34) 
Jejunum 100 50-500 6.0 0.087 0.064-0.11 
(33,34) 
Ileum 100 50-500 6.0 0.035 0.026-0.044 
(33,34) 7.0 0.111 0.074-0.180 






a V~ = 100 ml after initial volumetric emptying period of 20 min. 
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M E T H O D  OF SOLUTION 
The differential equations describing the model system can be written 
in matrix form 
x' = Ax (4) 
where x is the vector of amounts in the various compartments and A the 
coefficient matrix. 
Analytical solutions are obtained using eigenvalue theory with the aid 
of an IBM-AT computer and the IMSL math /PC library of subroutines. 
FORTRAN programs were written to simulate concentration-time profiles 
for each compartment, the absorption rate from each GI compartment , the 
gastric emptying rate, the fraction of dose absorbed from each GI compart- 
ment, and the fraction of dose emptied from the stomach versus time. The 
absorption rate or input of drug into the plasma from the GI tract is equal 
to 
I ( t )  = Kas(as) + K,d(a,~)  + Ka j (A j )  + Kai(Ai) (5) 
The amounts of the dose absorbed from the stomach, duodenum , jejunum, 
ileum, and combined compartments versus time (t) were determined by 
integrating numerically the appropriate terms from 0 to t using the 
trapezoidal rule. The emptying rate of drug from the stomach is equal to 
d M / d t ( s  - d )  = D E R  = Q~/V~(As)  (6) 
RESULTS AND DISCUSSION 
The effect of time of dose aministration relative to fasted state phasic 
activity was studied by administering the drug at every minute in a theoretical 
motility cycle (i.e., at the beginning of Phase I, 1 min into Phase I, etc.). 
Simulations of the plasma drug concentration-time profiles showing this 
effect can be found in Fig. 3. 
The simulated plasma level time curves clearly indicate that double 
peaks can occur as a result of variable gastric emptying. The plasma level 
curve is defined mathematically as having double peaks if the curve exhibits 
two maximas. Whether or not a double peak occurs in the plasma level 
curve is highly dependent on the flow rate out of the stomach after dosing 
and the time of dose administration relative to the MMC cycle. As a result 
of these simulations, four regions have been defined based on the shape of 
the predicted plasma level profiles (Fig. 2). Type A [Cpma• ) < Cpmax(2)] 
occurs when the drug is administered during the first 15 min of Phase I 
activity in the stomach. Type B (single peak) occurs when the drug is 
administered anywhere from 15 min into Phase I to the beginning of Phase 
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Fig. 3. Illustration of  mean plasma concentration time profiles of  cimetidine 
when drug is dosed in region A ( ), region B ( - - - - - ) ,  region C (- - -)  and 
region D ( . . . . .  ) (see Fig. 2). 
II, 60 min (15-60 min). Type C [ C p m a x ( 1  ) > Cpmax(2)] occurs when the drug 
is administered from the beginning of Phase II to 30 min into Phase II 
(60-90). Type D [ Corn,x(1) = Cpmax(2)] occurs when the drug is administered 
close to or in conjunction with the MMC in the stomach, and includes the 
remainder of the motility cycle (90-105 min). 
If the drug is dosed in region A, the average plasma profile exhibits 
double peaks where Cprnax(1 )  is less than Cpm~,x(2) (Fig. 3). After an initial 
volumetric emptying period of 20 rain, the rate of gastric emptying becomes 
relatively slow due to the quiescent phase. As a result, the drug is retained 
in the stomach and drug concentrations in the intestine and plasma fall. At 
the beginning of Phase II, approximately 50% of the dose remains in the 
stomach (Fig. 4). Therefore, an increased flow rate at 45-60 min results in 
an increase in absorption substantial enough to cause a double peak. The 
predicted probability of a plasma level curve exhibiting this shape was 
estimated by dividing the number of simulations showing this shape by the 
total number of simulations (15/105 = 14%). 
In contrast, if the drug is administered in region B, the plasma level 
curve exhibits only a single peak (Fig. 3). The concentration of drug in the 
intestinal compartments also approaches a single peak. As the drug is 
administered later in gastric Phase I activity, the duration of the quiescent 
period after initial volumetric emptying decreases and plasma levels do not 
fall as a result of slower emptying. The concentration of drug in the plasma 
does not peak until 60 min at which time approximately 75% of the dose 
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Fig. 4. Fraction of dose emptied from the stomach vs. time: (----)  region A; 
( ) region B; ( - - - - - )  region C; ( . . . .  ) region D. 
has already left the stomach (see Fig. 4). The next increase in Q~ occurs at 
105-150 min after dosing, but has little impact  on the plasma level curve 
since most of  the dose has already emptied the stomach. The predicted 
probabili ty of  a plasma level curve showing only a single peak is approxi- 
mately 43 %. 
In contrast to region A, dosing in region C occurs closer to Phase I I I  
in the stomach. Therefore Cpmax(1) is greater than Cpmax(2) (Fig. 3). 
However,  a second peak is possible because Phase I activity commences 
within a short time after dosing and lasts long enough to allow for a sufficient 
delay in stomach emptying of the drug. The predicted probability of  this 
curve shape is approximately 29%. 
I f  the drug is administered in region D, double peaks of approximately 
equal magnitude occur (Fig. 3). In this case, an MMC occurs coincident 
with dosing. Approximately 14% of the simulated plasma level curves 
showed this type of a profile. The average of all simulations indicates that 
the mean plasma level curve will tend to exhibit only a single peak. 
The effect of  dosing time relative to phasic activity is notable in the 
curves for the first several hours after which time no real differences between 
them are apparent.  Plasma levels are relatively insensitive to variability in 
gastric emptying rates and intestinal flow rates after 120 min because approx- 
imately 85% of the dose has already been absorbed. 
I f  the flow rates exiting the intestinal compartments  are varied, but the 
flow rate out of  the stomach is held constant, the simulated plasma level 
curves do not exhibit double peaks. Since the absorption rate constants in 
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Fig. 5. Absorption rate of  drug from the gastrointestinal tract vs. time: ( - - - - )  
region A; ( ) region B; ( - - - - - )  region C; ( . . . .  ) region D. 
the intestinal compartments are not drastically different from each other, 
the variability of the residence time in each intestinal compartment does 
not result in substantial variability in the overall absorption rate. 
In general, however, some drugs may be absorbed at different rates 
from each intestinal location. Some examples may be weak electrolytes with 
p Ka's in the range of intestinal p H or nonpassively absorbed drugs. Variable 
flow through the small intestine may contribute to variable absorption rate 
and plasma level profiles of these drugs. Therefore, a general model contain- 
ing separate intestinal compartments may be necessary for other drugs. 
Figures 4 and 5 simulate the fraction of dose emptied, and absorption 
rate versus time, respectively, corresponding to the plasma level curves 
discussed above. Double peaks in the overall absorption rate profile correlate 
well with double peaks in the plasma level curves. Emptying patterns of  
the drug from the stomach also correlate closely with plasma level curves. 
The model suggests that gastric emptying is a major factor controlling initial 
plasma levels of cimetidine. 
Frequency of Double Peaks; Comparison of Simulated and Observed 
Results 
Simulated data were compared to the results obtained by Walkenstein 
et al. (9) and Berardi et aI. (36, personal communication). The blood level 
curves after oral administration of cimetidine exhibited double peaks in 
approximately 50-75% of  the subjects studied. Approximately 57% of the 
theoretical curves discussed above exhibited double peaks. 
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The shapes of the experimental individual plasma level profiles were 
categorized similar to simulated data as four types. The profile is type A, 
C, or D if Cvma• is less than Cpmax(2), greater than Cpma• ) or approxi- 
mately equal to Cpmax(2), respectively. Type B is defined as only a single 
peak. 
This model differs from other models in its capacity to predict the 
frequency of double peaks expected. The probabilities predicted by the 
model are based on available physiological data (i.e., lengths of the fasted 
state motility phases, flow rates, etc.) and pharmacokinetic data of 
cimetidine (elimination rate, absorption rate, etc.). The model predicts 14.3, 
42.8, 28.6, and 14.3% of all curves should have shape A, B, C, and D, 
respectively. Given the fact that cimetidine would have been administered 
to fasted subjects at a random time in their motility cycles during a phar- 
macokinetic study, we would expect the percentages of experimental curves 
having shape A, B, C, or D to correlate with theoretical predictions if 
variable gastric emptying due to the motility cycle is responsible for the 
double peaks. 
The predicted frequency of double peaks and the shapes of the plasma 
level curyes correlate extremely well with experimental results from three 
separate studies (Fig. 6) (9, 36, personal communication). This agreement 
supports the hypothesis that double peaks are a result of variable and 
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Fig. 6. Frequency of double peaks: theoretical vs. experimental. (lst bar) theoreti- 
cal; (2nd bar) Walkenstein et aL (9); (3rd bar) Berardi-study A (personal communi- 
cation); (4th bar) Berardi-study B (personal communication). 
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delayed emptying of the drug from the stomach associated with the motility 
cycle. 
Effect of Motility Cycle and Phase Length 
The length of the motility cycle, Phases i, II, and III were reasonably 
altered to investigate their influence on the plasma drug level curves and 
frequency of double peaks. The duration of each phase influences the 
predicted frequency of double peaks (Fig. 7). If the duration of Phase I is 
long relative to Phase If, the probability of the plasma level curve exhibiting 
double peaks is higher than if the duration of Phases I and II is equal. 
Conversely, if Phase II is longer than Phase I, the probability of double 
peaks is slightly less than if the duration of Phases I and II is equal. Since 
20% of all MMCs do not include an antral component (24,25), this situation 
was simulated by only including Phases I and II in the stomach for all 
simulations. In this extreme case, the model predicts double peaks will 
occur more often, approximately 67% of the time. increasing the flow rate 
exiting the stomach (qs) or decreasing the volume of the stomach (vs) will 
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LENGTH OF PHASE [N THE STOMACH 
Fig. 7. The effect of motility phase length on the predicted frequency of double peaks. (A), Phase 
[-60min, Phase II-40mjn, Phase lII-0min; (B), Phase 1-60min, Phase It-40min, Phase 
II[-5 min; (C), Phase 1-40 rain, Phase II-40 rain, Phase III-5 rain; (D), Phase 1-60min, Phase 
II-80 vain, Phase III-5 rain. 
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Sampling Considerations 
The sampling scheme of the experimental data cited above included 
time points of 0, 15, 30, 45, 60, 90, 120, 180, 240, and 360 min. The sampling 
times could alter the observed frequency of double peaks. However, if only 
the predicted plasma levels at times comparable to a typical sampling scheme 
were used, the percentages of theoretical curves having shapes A, B, C, and 
D were not altered significantly. 
SUMMARY 
The simulations suggest that the MMC and associated variability in 
stomach emptying rates can result in double peaks in the plasma level curve 
of cimetidine. The following physiological factors are important with respect 
to the appearance of double peaks in and the shapes of the plasma level 
curves: (i) the dosing time relative to phasic activity; (ii) variability in 
emptying rates after dosing; (iii) the length of each motility phase, par- 
ticularly the quiescent period, after dosing; and (iv) the stomach emptying 
rates as a function of phasic activity. 
Since the model is based on a physiological cycle, it is possible to 
predict the frequency of double peaks. The frequency of theoretical curve 
types A, B, C, and D correlates extremely well with experimental data 
indicating that variability in gastric emptying rates associated with the fasted 
state motility cycle is a plausible explanation for the double peak 
phenomenon. This explanation for observed plasma level double peaks 
provides an alternative to enterohepatic recycling or two-site absorption. 
The capacity of the model to predict frequency is something other 
models have been unable to do. Because of this capacity, the legitimacy of 
the motility cycle as a cause of double peaks can be tested with already 
available experimental plasma level data. Human studies are being con- 













Amount of drug in the stomach 
Amount of drug in the duodenum 
Amount of drug in the jejunum 
Amount of drug in the ileum 
Amount of drug in the plasma 
Amount of drug in the peripheral compartment 
Flow rate exiting the stomach 
Flow rate exiting the duodenum 
Flow rate exiting the jejunum 
Flow rate exiting the ileum 
Volume of stomach contents 


















Volume of duodenal contents 
Volume of jejunal contents 
Volume of ileal contents 
Volume of distribution 
Initial volume of stomach contents 
Absorption rate constant of cimetidine from the stomach 
Absorption rate constant of cimetidine from the duodenum 
Absorption rate constant of cimetidine from the jejunum 
Absorption rate constant of cimetidine from the ileum 
Distribution rate constant of cimetidine from plasma to tissue 
Distribution rate constant of cimetidine from tissue to plasma 
Elimination rate constant of cimetidine from the plasma 
Input of drug into the plasma from thegastrointestinal tract 
Emptying rate of the drug from the stomach into the duodenum 
First maximum drug concentration in the plasma 
Second maximum drug concentration in the plasma 
Time Of first maximum drug concentration in the plasma 
Time of second maximum drug concentration in the plasma 
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